8-K: Telomir Pharmaceuticals Secures $3 Million Equity Investment at Premium to Advance Rare Disease Program

Telomir Pharmaceuticals raised $3 million through a direct equity investment from its largest shareholder to support regulatory and development activities, including an upcoming IND submission for a rare disease indication.

Summary

• Telomir Pharmaceuticals secured $3 million in equity financing on May 19, 2025, through a direct investment by The Bayshore Trust, an entity affiliated with the company's largest shareholder.
• The transaction involved the issuance of 1 million restricted shares of common stock at $3.00 per share, an 18% premium to the closing share price of $2.54 on the date of execution.
• This follows a prior $1 million equity investment at $7.00 per share made on December 9, 2024, and complements an existing $5 million non-dilutive line of credit from the same group, which remains undrawn.
• The proceeds are intended to support regulatory and development activities, including the planned IND submission for Telomir-1 in a rare disease indication.

Sentiment

Score: 8

Explanation: The announcement is positive due to the successful capital raise at a premium, which strengthens the company's financial position and supports its key development programs. The insider participation also signals confidence in the company's prospects.

Positives

• The $3 million equity investment strengthens the company's balance sheet.
• The investment at a premium signals strong insider conviction.
• The funds will support the advancement of Telomir-1's IND submission for a rare disease.
• The financing was structured as a straight equity deal with no warrants, discounts, or convertible features, minimizing dilution.
• The company has an additional $5 million non-dilutive line of credit available.

Future Outlook

Proceeds from the offering are expected to support regulatory and development activities, including the planned IND submission for Telomir-1 in a rare disease indication.

Industry Context

The financing reflects continued investor interest in companies developing therapies for rare diseases, which often benefit from expedited regulatory pathways and market exclusivity.

Related Party Transactions

• The equity financing was provided by The Bayshore Trust, an entity affiliated with the company's largest shareholder.

Stakeholder Impact

• Shareholders benefit from the strengthened balance sheet and advancement of the Telomir-1 program.
• The company is better positioned to pursue its development goals, potentially leading to new therapies for rare diseases.

Next Steps

• Proceed with the planned IND submission for Telomir-1 in a rare disease indication.
• Utilize the proceeds to support regulatory and development activities.

Key Dates

Keywords

equity financing, Telomir Pharmaceuticals, rare disease, IND submission, investment, TELO, shareholder